What is Cellectis?
Founded in 1999 and headquartered in Paris, France, Cellectis is a biopharmaceutical firm dedicated to developing novel pharmaceutical products and therapies. As a publicly traded entity since 2019, the company operates across Europe and North America, serving both B2B and B2C markets. Cellectis leverages advanced technology, including mobile applications, to support its operations and product development. The company's focus on innovative therapies places it within a dynamic and competitive sector of the healthcare industry, aiming to address unmet medical needs through cutting-edge research and development.
How much funding has Cellectis raised?
Cellectis has raised a total of $521.5M across 5 funding rounds:
Corporate Investment
$22.2M
Stock Offering
$129M
Stock Offering
$163.7M
Other Financing Round
$164M
Debt
$42.6M
Corporate Investment (2014): $22.2M with participation from venBio, OrbiMed, Aquilo Capital Management, Merlin Nexus, and Ridgeback Capital
Stock Issuance/Offering (2015): $129M led by Undisclosed
Stock Issuance/Offering (2018): $163.7M supported by Citi, Goldman Sachs & Co, and Barclays
Other Financing Round (2018): $164M featuring Undisclosed
Debt (2022): $42.6M backed by European Investment Bank
Key Investors in Cellectis
European Investment Bank
European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution, established in 1958 and headquartered in Luxembourg, providing crucial financial backing for strategic projects.
venBio
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs and positioning its portfolio companies for success.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms, with deep expertise in life sciences and healthcare business development.
What's next for Cellectis?
The recent major strategic investment in Cellectis, following substantial prior financing rounds, indicates a strong confidence in the company's long-term growth strategy and its potential to disrupt the biopharmaceutical market. This capital infusion is expected to accelerate the development and commercialization of its therapeutic candidates, potentially leading to expanded clinical trials and market penetration. Cellectis's continued pursuit of enterprise-level funding suggests a trajectory towards scaling its operations and solidifying its position as a key player in the development of next-generation medicines.
See full Cellectis company page
